BofA initiated coverage of Beta Bionics (BBNX) with a Buy rating and $25 price target Beta’s iLet insulin pump simplifies insulin-dosing for insulin intensive diabetic patients with its ...

Adults with type 1 diabetes who initiated treatment with a bionic pancreas at a primary care site experienced similar glycemic benefits as those starting the device through an endocrinologist, ...

Expanding its portfolio, the company is introducing the Patch Pump and developing the bi-hormonal iLet while forging partnerships to refine automated insulin and glucagon delivery. Beta Bionics ...

The artificial pancreas device combines an under-the-skin sensor to measure blood glucose with existing insulin pump technology ... Administration cleared the iLet Bionic Pancreas technology ...

The Food and Drug Administration cleared iLet for use in Type 1 diabetes in the U.S. in 2023. The device combines a pump with software that calculates insulin dosing, eliminating the need for ...

The so-called 'hybrid closed-loop' system comprises a blood glucose sensor, the MiniMed 670G insulin pump and an infusion ... Beta Bionics' iLet has shown promise in clinical trials so far.

The company’s iLet Bionic Pancreas is an insulin delivery device for treating type 1 diabetes in adults and children six years of age and older. Beta Bionics is also developing Patch Pump ...